Yan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Yu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Wei Han
Laboratory of Regeneromics, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, PR China
17 shared publications Jin Gao
Laboratory of Regenerative Medicine, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
11 shared publicationsYang Zhang
Laboratory of Regeneromics, School of Pharmacy, Shanghai Jiao Tong University, NO.800, Dongchuan Road, Shanghai, 200240, China
10 shared publicationsQing Deng
Shanghai Municipality Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, NO.800, Dongchuan Road, Shanghai, 200240, China; Laboratory of Regeneromics, School of Pharmacy, Shanghai Jiao Tong University, NO.800, Dongchuan Road, Shanghai, 200240, China
9 shared publicationsWen Guan
Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University , GuangZhou , People's Republic of China
9 shared publicationsHao Ye
Laboratory of Regeneromics, School of Pharmacy, Shanghai Jiao Tong University, NO.800, Dongchuan Road, Shanghai, 200240, China
8 shared publications
Latest Publications
- Open Access
- 29 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4711
Development of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments
G-protein-coupled receptors (GPCRs), especially chemokine receptors, are ideal targets for monoclonal antibody drugs. Considering the special multi-pass transmembrane structure of GPCR, it is often a laborious job to obtain antibody information about off-targets and epitopes on antigens. To accelerate the process, a rapid and simple method needs to be developed. The split-ubiquitin-based yeast two hybrid system (YTH) was used as a blue script for a new method. By fusing with transmembrane peptides, scFv antibodies were designed to be anchored on the cytomembrane, where the GPCR was co-displayed as well. The coupled split-ubiquitin system transformed the scFv-GPCR interaction signal into the expression of reporter genes. By optimizing the topological structure of scFv fusion protein and key elements, including signal peptides, transmembrane peptides, and flexible linkers, a system named Antigen-Antibody Co-Display (AACD) was established, which rapidly detected the interactions between antibodies and their target GPCRs, CXCR4 and CXCR5, while also determining the off-target antibodies and antibody-associated epitopes. The AACD system can rapidly determine the association between GPCRs and their candidate antibodies and shorten the research period for off-target detection and epitope identification. This system should improve the process of GPCR antibody development and provide a new strategy for GPCRs antibody screening.
- 29 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4711
Open AccessDevelopment of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments
G-protein-coupled receptors (GPCRs), especially chemokine receptors, are ideal targets for monoclonal antibody drugs. Considering the special multi-pass transmembrane structure of GPCR, it is often a laborious job to obtain antibody information about off-targets and epitopes on antigens. To accelerate the process, a rapid and simple method needs to be developed. The split-ubiquitin-based yeast two hybrid system (YTH) was used as a blue script for a new method. By fusing with transmembrane peptides, scFv antibodies were designed to be anchored on the cytomembrane, where the GPCR was co-displayed as well. The coupled split-ubiquitin system transformed the scFv-GPCR interaction signal into the expression of reporter genes. By optimizing the topological structure of scFv fusion protein and key elements, including signal peptides, transmembrane peptides, and flexible linkers, a system named Antigen-Antibody Co-Display (AACD) was established, which rapidly detected the interactions between antibodies and their target GPCRs, CXCR4 and CXCR5, while also determining the off-target antibodies and antibody-associated epitopes. The AACD system can rapidly determine the association between GPCRs and their candidate antibodies and shorten the research period for off-target detection and epitope identification. This system should improve the process of GPCR antibody development and provide a new strategy for GPCRs antibody screening.
- 1 April 2020
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 147, 105301
Pharmacokinetics of midkine with different N-terminal structures in rats
- 1 April 2020
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 147, 105301
Pharmacokinetics of midkine with different N-terminal structures in rats
- 1 January 2020
- Published by Elsevier in Cellular Signalling
- Vol. 65, 109423
Midkine promotes articular chondrocyte proliferation through the MK-LRP1-nucleolin signaling pathway
- 1 January 2020
- Published by Elsevier in Cellular Signalling
- Vol. 65, 109423
Midkine promotes articular chondrocyte proliferation through the MK-LRP1-nucleolin signaling pathway
- Open Access
- 5 August 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (11) , 12135-12145
IL‐1Ra protects hematopoietic cells from chemotoxicity through p53‐induced quiescence
The protection of constantly proliferating gut epithelia and hematopoietic tissues from cytotoxicity could improve conventional chemotherapy efficacy and widen its therapeutic window. Previously, we reported that, in mouse models, pretreatment of recombinant human IL‐1 receptor antagonist (rhIL‐1Ra) protected both types of vulnerable tissues from chemotherapeutics. Here, we showed that rhIL‐1Ra treatment up‐regulated the protein levels of phosphorylated p38, p53, and p21 and induced transient hematopoietic stem/progenitor cell (HS/PC) quiescence. Knockout of IL‐1 receptor I ( IL‐1RI ), p53 , or p21 alleles and pharmacological inactivation of p38 mapped the rhIL‐1Ra pathway in the induction of HS/PC quiescence. Therefore, rhIL‐1Ra administration before but not after chemotherapy alleviated 5‐fluorouracil‐induced neutropenia. In addition, in vivo and in vitro cell proliferation assays revealed that the rhIL‐1Ra treatment did not affect cancer cell proliferation or chemosensitivity. Lastly, we propose an IL‐1/IL‐1Ra pathway (IL‐1RI → p38 → p53 → p21), which regulates HS/PC quiescence. The rhIL‐1Ra may provide a new route for p53‐based cyclotherapy, which spares normal cells but kills cancer cells during chemotherapy.—Ye, H., Qian, L., Zhu, S., Deng, S., Wang, X., Zhu, J., Chan, G. L., Yu, Y., Han, W. IL‐1Ra protects hematopoietic cells from chemotoxicity through p53‐induced quiescence. FASEB J. 33, 12135‐12145 (2019). www.fasebj.org
- 5 August 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (11) , 12135-12145
Open AccessIL‐1Ra protects hematopoietic cells from chemotoxicity through p53‐induced quiescence
The protection of constantly proliferating gut epithelia and hematopoietic tissues from cytotoxicity could improve conventional chemotherapy efficacy and widen its therapeutic window. Previously, we reported that, in mouse models, pretreatment of recombinant human IL‐1 receptor antagonist (rhIL‐1Ra) protected both types of vulnerable tissues from chemotherapeutics. Here, we showed that rhIL‐1Ra treatment up‐regulated the protein levels of phosphorylated p38, p53, and p21 and induced transient hematopoietic stem/progenitor cell (HS/PC) quiescence. Knockout of IL‐1 receptor I ( IL‐1RI ), p53 , or p21 alleles and pharmacological inactivation of p38 mapped the rhIL‐1Ra pathway in the induction of HS/PC quiescence. Therefore, rhIL‐1Ra administration before but not after chemotherapy alleviated 5‐fluorouracil‐induced neutropenia. In addition, in vivo and in vitro cell proliferation assays revealed that the rhIL‐1Ra treatment did not affect cancer cell proliferation or chemosensitivity. Lastly, we propose an IL‐1/IL‐1Ra pathway (IL‐1RI → p38 → p53 → p21), which regulates HS/PC quiescence. The rhIL‐1Ra may provide a new route for p53‐based cyclotherapy, which spares normal cells but kills cancer cells during chemotherapy.—Ye, H., Qian, L., Zhu, S., Deng, S., Wang, X., Zhu, J., Chan, G. L., Yu, Y., Han, W. IL‐1Ra protects hematopoietic cells from chemotoxicity through p53‐induced quiescence. FASEB J. 33, 12135‐12145 (2019). www.fasebj.org
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 854, 338-346
rhIL-1Ra reduces hepatocellular apoptosis in mice with acute liver failure mainly by inhibiting the activities of Kupffer cells
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 854, 338-346
rhIL-1Ra reduces hepatocellular apoptosis in mice with acute liver failure mainly by inhibiting the activities of Kupffer cells
- 1 February 2019
- Published by Elsevier in Cancer Letters
- Vol. 443, 1-12
Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer
- 1 February 2019
- Published by Elsevier in Cancer Letters
- Vol. 443, 1-12
Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer
- Open Access
- 23 January 2019
- Published by The Royal Society in Open Biology
- Vol. 9 (1) , 180238
Large-scale gene analysis of rabbit atherosclerosis to discover new biomarkers for coronary artery disease
Atherosclerosis is the pathological basis of coronary artery disease (CAD) and causes high mortality. Thus, early detection is thought to be crucial in reducing the risk of CAD. Uncovering the mechanisms of the progression and regression of atherosclerosis will provide insights into discovering novel biomarkers to identify subjects at risk for CAD and improve prevention. We established atherosclerosis progression and regression in a rabbit model. Then, we extracted mRNA of the abdominal aorta from control, model and recovery groups to perform gene chip analysis. Candidate biomarkers were screened by large-scale gene analysis and validated in patients with CAD or with CAD recovery by ELISA. The differentially expressed genes in the progression and regression of atherosclerosis were mainly enriched in four clusters. Genes associated with inflammation and extracellular matrix were returned to normal or close-to-normal levels much earlier than genes associated with metabolism and sarcoplasmic proliferation, and they were maintained downregulated or upregulated after feeding a normal diet. We then selected four candidate biomarkers and found that lipoprotein lipase (LPL), bone morphogenetic protein 7 and somatostatin concentrations could indicate CAD diagnosis. In addition, LPL and macrophage cationic peptide 2 can be indicators of the prognosis of CAD. Molecular changes during the progression and regression of atherosclerosis in rabbits were revealed, and candidate regulators were identified. The identified factors could be used as novel biomarkers and targets for improving the diagnosis and prognosis of human CAD in the future.
- 23 January 2019
- Published by The Royal Society in Open Biology
- Vol. 9 (1) , 180238
Open AccessLarge-scale gene analysis of rabbit atherosclerosis to discover new biomarkers for coronary artery disease
Atherosclerosis is the pathological basis of coronary artery disease (CAD) and causes high mortality. Thus, early detection is thought to be crucial in reducing the risk of CAD. Uncovering the mechanisms of the progression and regression of atherosclerosis will provide insights into discovering novel biomarkers to identify subjects at risk for CAD and improve prevention. We established atherosclerosis progression and regression in a rabbit model. Then, we extracted mRNA of the abdominal aorta from control, model and recovery groups to perform gene chip analysis. Candidate biomarkers were screened by large-scale gene analysis and validated in patients with CAD or with CAD recovery by ELISA. The differentially expressed genes in the progression and regression of atherosclerosis were mainly enriched in four clusters. Genes associated with inflammation and extracellular matrix were returned to normal or close-to-normal levels much earlier than genes associated with metabolism and sarcoplasmic proliferation, and they were maintained downregulated or upregulated after feeding a normal diet. We then selected four candidate biomarkers and found that lipoprotein lipase (LPL), bone morphogenetic protein 7 and somatostatin concentrations could indicate CAD diagnosis. In addition, LPL and macrophage cationic peptide 2 can be indicators of the prognosis of CAD. Molecular changes during the progression and regression of atherosclerosis in rabbits were revealed, and candidate regulators were identified. The identified factors could be used as novel biomarkers and targets for improving the diagnosis and prognosis of human CAD in the future.
- 1 October 2017
- Published by Elsevier in Protein Expression and Purification
- Vol. 138, 81-87
Production of bioactive recombinant rat soluble receptor for advanced glycation end products (rrsRAGE) in Pichia pastoris
- 1 October 2017
- Published by Elsevier in Protein Expression and Purification
- Vol. 138, 81-87
Production of bioactive recombinant rat soluble receptor for advanced glycation end products (rrsRAGE) in Pichia pastoris
- Open Access
- 12 June 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (2) , 1001-1008
Anti-CXCL4 monoclonal antibody accelerates telogen to anagen transition and attenuates apoptosis of the hair follicle in mice
Although hair loss or alopecia is a common disease, its exact mechanisms are not yet well understood. The present study investigated the hypothesis that the homeostatic regulation of genes during hair regeneration may participate in hair loss, based on the cyclicity of hair growth. A cluster of such genes was identified by an expression gene‑array from the dorsal skin in a depilated mouse model, and CXCL4 was identified as a significantly regulated gene during the hair regeneration process. To elucidate the function of CXCL4 in hair growth, CXCL4 activity was blocked by the administration of an anti‑CXCL4 monoclonal antibody (mAb). Histomorphometric analysis indicated that anti‑CXCL4 mAb induced an earlier anagen phase and delayed hair follicle regression, in contrast with that in the control group. Moreover, CXCL4 mAb upregulated the transcription levels of several hair growth‑related genes, including Lef1, Wnt10b, Bmp4 and Bmp2. In addition, CXCL4 mAb increased the levels of the proliferation‑related protein PCNA and Bcl‑2 during the anagen phase, while it reduced the expression of pro‑apoptotic protein Bax and cleaved caspase‑3 during the catagen phase. These findings reveal that CXCL4 plays an important role in hair growth, and that blockade of CXCL4 activity promotes hair growth.
- 12 June 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (2) , 1001-1008
Open AccessAnti-CXCL4 monoclonal antibody accelerates telogen to anagen transition and attenuates apoptosis of the hair follicle in mice
Although hair loss or alopecia is a common disease, its exact mechanisms are not yet well understood. The present study investigated the hypothesis that the homeostatic regulation of genes during hair regeneration may participate in hair loss, based on the cyclicity of hair growth. A cluster of such genes was identified by an expression gene‑array from the dorsal skin in a depilated mouse model, and CXCL4 was identified as a significantly regulated gene during the hair regeneration process. To elucidate the function of CXCL4 in hair growth, CXCL4 activity was blocked by the administration of an anti‑CXCL4 monoclonal antibody (mAb). Histomorphometric analysis indicated that anti‑CXCL4 mAb induced an earlier anagen phase and delayed hair follicle regression, in contrast with that in the control group. Moreover, CXCL4 mAb upregulated the transcription levels of several hair growth‑related genes, including Lef1, Wnt10b, Bmp4 and Bmp2. In addition, CXCL4 mAb increased the levels of the proliferation‑related protein PCNA and Bcl‑2 during the anagen phase, while it reduced the expression of pro‑apoptotic protein Bax and cleaved caspase‑3 during the catagen phase. These findings reveal that CXCL4 plays an important role in hair growth, and that blockade of CXCL4 activity promotes hair growth.